Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Male and non-pregnant, non-lactating female subjects.~* Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain intensity (NRS) of 5 points or higher.~* Subjects who are opioid-naïve or pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.~* Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the trial.~* Expected course of the disease and the pain that would permit compliance with the trial protocol over the entire trial period.~Exclusion Criteria~Key Exclusion Criteria:~* Subjects will be excluded from the study if they have a history of seizure disorder or epilepsy;~* known history and/or presence of cerebral tumor or cerebral metastases.~* history of alcohol or drug abuse;~* uncontrolled hypertension,~* clinical laboratory values reflecting severe renal insufficiency,~* moderate or severe hepatic impairment,~* hepatitis B or C, HIV,~* inadequate bone marrow reserve~* currently treated with radiotherapy,~* pain-inducing chemotherapy,~* anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitor (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial.~* selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Matching Placebo after Tapentadol in Titration Phase (Type: PLACEBO_COMPARATOR): Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
- Morphine Controlled Release (Type: ACTIVE_COMPARATOR): Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
- Tapentadol Prolonged Release (Type: EXPERIMENTAL): Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).